Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a note issued to investors on Friday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price for the company.

Lipocine Price Performance

Lipocine stock opened at $4.45 on Friday. The company has a market cap of $23.81 million, a PE ratio of -5.86 and a beta of 1.23. Lipocine has a 12 month low of $3.20 and a 12 month high of $11.79. The company has a fifty day moving average price of $4.89 and a two-hundred day moving average price of $5.04.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. Equities research analysts anticipate that Lipocine will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP acquired a new position in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent SEC filing. 9.11% of the stock is owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.